Jun 12
$KYMR - Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT621 a FirstinClass Oral STAT6 Degrader at the Japanese Dermatological Association Annual Meeting
Oral presentation at JDA features new data from the KT-621 Phase 1 study… ift.tt/aGEcym1
2
172
$KYMR - Kymera Therapeutics Presents New Preclinical Lupus Data for KT579 FirstinClass Oral IRF5 Degrader at EULAR and FOCIS Congresses
KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active t… ift.tt/QcgyJYF
201
🚨 $NRIX (Nurix Therapeutics) – Massive $2.3 Billion Deal with Roche
Roche acquires global rights to bexobrutideg, Nurix’s experimental BTK degrader for blood cancers.
Deal Highlights
Total Potential Value: Up to $2.3 Billion
Upfront Payment: $700 Million (cash)
Structure: Roche and Nurix will split U.S. development costs and profits 50/50
ExU.S. Rights: Roche gets full rights outside the U.S. (with royalties to Nurix)
Drug Profile
Bexobrutideg: A firstinclass BTK degrader (not just inhibitor)
Designed to completely eliminate the cancerdriving BTK protein
Potential to overcome resistance seen with current BTK inhibitors (Imbruvica, Calquence, etc.)
Targeting Bcell malignancies (e.g., CLL, mantle cell lymphoma, etc.)
Quick Takeaways
One of the largest biotech deals of 2026 — huge validation for Nurix’s protein degradation platform.
$700M upfront gives Nurix massive cash runway and derisks their lead program.
Roche gains a potentially bestinclass BTK degrader to strengthen its oncology portfolio.
Nurix keeps significant U.S. economics (50% profit share) — very shareholderfriendly structure.
Market Reaction Expectation:
This is a major win for $NRIX . Expect a strong positive move when the market opens (pending any broader riskoff sentiment).
Bottom Line:
Nurix just secured a transformative partnership with one of the world’s top pharma companies. This dramatically boosts credibility for their degradation platform and provides substantial nondilutive capital.
Would you like key financial implications, comparison to similar deals, or potential stock catalysts?
1
1
253
Psilera has closed an oversubscribed $8.8M raised #SeriesSeed funding round!
#FirstInClass and #FirstInHuman data expected in 2027.
Read the full details in the press release below: prnewswire.com/news-releases…
#MindfulMedicine #Psychedelics #Neuroplastogens
1
1
7
1,128
May 15
Moscow narrows drug development subsidies as budget deficit tightens
#Politics #Topstories #bestinclass #budgetdeficit #drugdevelopment #firstinclass #healthpolicy #pharmaceuticals #Russia #24brussels #breaking #news #europe #brussels #belgium
24brussels.online/politics/m…
7
#HAYA is heading to the #RIS2026!
Connect with our #CBO, @drrichjlaw to learn about our #Pulmonary programs focused on advancing #FirstInClass solutions for the #Treatment of #IPF by leveraging #noncodingRNAs.🫁🧬
If you attending, let’s connect!🤝
3
4
830
Apr 24
🔬New Releases | Over 1,000 new research molecules are now available.
This release expands key areas across #Oncology, #Neurology, #Immunology & Inflammation, #Metabolic, and #Cardiovascular research—supporting a wide spectrum of discovery needs.
🎯 Target coverage includes #BCL2, #KRASG12C, #PPARα, #5HT2A, #JAK/TYK2, and #METTL1, enabling deeper exploration of critical pathways and mechanisms.
💡 The collection features multiple #firstinclass and #clinicalstage compounds, with optimized properties such as:
– Oral bioavailability
– Brain penetration
– High selectivity
Designed to strengthen your molecular toolbox for efficient #TargetValidation and #MechanismOfAction studies.
✨ Empower your research with high-quality molecular tools
⚡ Accelerate discovery with greater confidence
#DrugDiscovery #LifeScience #OncologyResearch #CardiovascularResearch #NewMolecules
2
3
133
Apr 20
Advancing cancer research together with MedChemExpress. Several drugs are being unveiled for the first time at the AACR 2026 Annual Meeting. Stop by Booth #1742 to explore how we can support your research. medchemexpress.com/MCE-AACR-…
#AACR #AACR2026 #drugdiscovery #firstinclass
Apr 19
🧬AACR 2026 New Molecule Readouts
AACR is ongoing. Here’s a look at the New Drugs emerging across #TPD, #ADCs, #bispecifics, and immune modulation.
01 | NEO-811
A molecular glue degrader targeting ARNT (HIF-1β), with strong single-agent activity in clear cell renal cell carcinoma (ccRCC).
02 | #AZD8359
A CD8-biased T cell engager designed to expand the therapeutic window in prostate cancer.
03 | #TNG961
A selective oral HBS1L molecular glue degrader for FOCAD-deficient cancers.
04 | #EPI-326
A mutation-agnostic EGFR bispecific that promotes EGFR degradation while sparing normal tissues in EGFR-driven solid tumors.
05 | E-688 (#HLX316)
A first-in-class B7-H3-targeted sialidase designed to enhance innate and adaptive anti-tumor immunity.
06 | #ECI830
A potent and selective CDK2 inhibitor targeting HR /HER2- breast cancer and CCNE1-amplified tumors.
07 | TRI-611
A CNS-penetrant ALK molecular glue degrader for ALK fusion-positive non-small cell lung cancer.
08 | CD30 ADC program
A dual-payload ADC combining MTI Topo1 inhibitors to overcome resistance mechanisms.
09 | CID-078
A first-in-class oral macrocyclic cyclin A/B–RxL inhibitor targeting RB1-deficient or E2F-driven cancers.
10 | AMX-883
An orally bioavailable BRD9 degrader acting as a differentiation therapy for acute myeloid leukemia (AML).
11 | ENPP3 ADC (JNJ-89862175)
A novel ENPP3-targeted ADC undergoing preclinical characterization in advanced solid tumors.
12 | #IPN01203
A dual T cell agonist designed to activate VB6/VB10 TCR-expressing T cells.
ow.ly/sP0950YMhUr
MedChemExpress welcomes you to Booth #1742 to connect and exchange ideas—and pick up exclusive lab merch and woven totes!
#NEO811 #E688 #TRI611 #CID078 #AMX883 #JNJ89862175 #TargetedProteinDegradation #MolecularGlue #Oncology #DrugDiscovery
3
3
309
First-in-Class defines a new mechanism. Best-in-Class refines it to outperform. In oncology, success often lies in who executes better, not just who gets there first.
#Oncology #DrugDevelopment #FirstInClass #BestInClass #Pharma
14
Mar 17
$CG - R1 Therapeutics launches with oversubscribed 775 million Series A financing to advance firstinclass treatment for hyperphosphatemia in patients with chronic kidney disease
News & Disclaimer
ift.tt/Z0TzulF
1
184
Mar 12
🔬February New Releases
🚀1,000 new research molecules are now available at MedChemExpress. This release focuses on key research areas including #Oncology, #Neurology, #Immunology & Inflammation, and #Cardiovascular Diseases, supporting diverse life science studies.
The newly released molecules cover important targets such as #Hsp70, #MDM2, #EGFR/HER2, #M4, #Keap1-Nrf2, and #IP6K, providing powerful tools for target investigation and biological research.
Several first-in-class and clinical-stage compounds are also included to further expand the toolbox for advanced drug discovery and mechanism studies.
✨Unlock deeper insights into key targets
⚡Accelerate mechanism research
#DrugDiscovery #TargetValidation #FirstInClass
3
26
Feb 16
【武田、oveporexton（TAK-861）のNT1向けNDAを米FDAが受理──優先審査を付与、PDUFAは2026年Q3見込み】 Takeda: U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Oveporexton (TAK-861) for Narcolepsy Type 1
STELLANEWS.LIFE AI Impact Assessment Rating (Reference): ★★★★☆ ※実験的指標であり、正確性は保証されない参考値
Read the full report here: stellanews.life/technology/8…
#Takeda #Oveporexton #TAK861 #Narcolepsy #FDA #PriorityReview #FirstInClass #OrexinAgonist #PDUFA
1
77
Brensocatib, Insmed’s first-in-class oral DPP1 inhibitor, progressed from early amidoacetonitrile leads through systematic medicinal chemistry optimization, addressing challenges in metabolic stability, oxidative liabilities, hERG risk, and aortic binding.
This article, written by our AiFChem internal experts, explores the chemical strategies behind the β-amino acid series that ultimately led to Brensocatib—a life-changing therapy for non-cystic fibrosis bronchiectasis (NCFB).
📖 Read on to explore the full expert insights: aifchem.com/blog-from-lead-t…
#AiFChem #DPP1Inhibitor #FirstInClass #DrugDiscovery
1
140
Feb 9
Grateful for this honour. Proud that Team RSKV No.2, Jama Masjid proves a government school stands tall in academic excellence. Thank you Hon’ble Minister Sh. Ashish Sood ji and the entire team for the encouragement. We remain committed to every child’s success. #FirstInClass
Feb 8
NewsX is thrilled to congratulate RSKV NO.2, Jama Masjid for winning the prestigious First In Class 2026 Award in the 'Best in Academics' category from Hon'ble Minister of Education of Delhi, Ashish Sood (
@ashishsood_bjp). The ceremony at the First In Class Conclave was held in the presence of Dr. Aishwarya Pandit Sharma (@DrAishwarya_PT).
#FirstInClass #ExcellenceInEducation
5
4
15
389
Feb 8
Government schools are redefining excellence.
Proud that RSKV No. 2, Jama Masjid is honoured as School of the Year – Best in Academics.
Thank you First in Class and The Sunday Guardian Foundation for recognising our work.
Grateful to Hon’ble Education Minister Shri Ashish Sood Sir for the encouragement.
This achievement belongs to every student and teacher who turns vision into results.
@RSKV_JM @Dir_Education @uma_kapur
#itvnews #newsX #Indianews #sgf
#firstinclass #TheSundayGurdgian
#GovernmentSchoolPride #ExcellenceInEducation #SchoolOfTheYear #RSKVJamaMasjid #Gratitude
13
10
34
1,320
Feb 8
NewsX is thrilled to congratulate SKV, Aram Bagh Lane for winning the prestigious First In Class 2026 Award in the 'Best Hindu Medium School' category from Hon'ble Minister of Education of Delhi, Ashish Sood (@ashishsood_bjp).
The ceremony at the First In Class Conclave was held in the presence of Dr. Aishwarya Pandit Sharma (@DrAishwarya_PT).
#FirstInClass #ExcellenceInEducation
1
149
Feb 8
NewsX is thrilled to congratulate Sarvodaya Bal Vidyalaya, Jama Masjid for winning the prestigious First In Class 2026 Award in the 'Best Urdu Medium School' category from Hon'ble Minister of Education of Delhi, Ashish Sood (@ashishsood_bjp).
The ceremony at the First In Class Conclave was held in the presence of Dr. Aishwarya Pandit Sharma (@DrAishwarya_PT).
#FirstInClass #ExcellenceInEducation
1
1
4
141
Feb 8
NewsX is thrilled to congratulate SKV, Baba Ram Dev, Prasad Nagar for winning the prestigious First In Class 2026 Award in the 'Best Girls School' category from Hon'ble Minister of Education of Delhi, Ashish Sood (@ashishsood_bjp).
The ceremony at the First In Class Conclave was held in the presence of Dr. Aishwarya Pandit Sharma (@DrAishwarya_PT).
#FirstInClass #ExcellenceInEducation
1
1
126
Feb 8
NewsX is thrilled to congratulate The Ardee School for winning the prestigious First In Class 2026 Award in the 'Best Mental Health Programme' category from Hon'ble Minister of Education of Delhi, Ashish Sood (@ashishsood_bjp).
The ceremony at the First In Class Conclave was held in the presence of Dr. Aishwarya Pandit Sharma (@DrAishwarya_PT).
#FirstInClass #ExcellenceInEducation
1
113